FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
5 reports, 1 independent
Updated 00:00
Still developing
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Clearmind Medicine Inc. held clinical trials at Yale and Johns Hopkins and submitted data to the FDA.1 source
Clearmind Medicine Inc. is undergoing FDA-overseen trials in the US and Israel.1 source
Clearmind Medicine Inc. achieves Nasdaq listing, FDA oversight, and clinical trial partnerships.1 source
Keep exploring
The entities involved
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- Capricor Therapeutics is seeking regulatory approval from the FDA for clinical trials and has listed on the Nasdaq stock exchange, with a law firm based in New York City involved.
- Decoy Therapeutics is listed on the Nasdaq stock exchange and is currently seeking expedited regulatory approval via FDA pathways.
- Arise is seeking FDA approval for a drug as of October 7, 2026.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
Coverage
Newest first; wire copies grouped- manilatimes.net
- manilatimes.net
- manilatimes.netClearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial
- manilatimes.net
- manilatimes.net